RT Journal Article
SR Electronic
T1 BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: preliminary findings from UK biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.05.20122226
DO 10.1101/2020.06.05.20122226
A1 Sattar, Naveed
A1 Ho, Frederick K
A1 Gill, Jason MR
A1 Ghouri, Nazim
A1 Gray, Stuart R
A1 Celis-Morales, Carlos A
A1 Katikireddi, S Vittal
A1 Berry, Colin
A1 Pell, Jill P
A1 McMurray, John JV
A1 Welsh, Paul
YR 2020
UL http://medrxiv.org/content/early/2020/06/17/2020.06.05.20122226.abstract
AB We examined the link between BMI and risk of a positive test for SARS-CoV-2 and risk of COVID-19-related death among UK Biobank participants. Among 4855 participants tested for SARS-CoV-2 in hospital, 839 were positive and of these 189 died from COVID-19. Poisson models with penalised thin plate splines were run relating exposures of interest to test positivity and case-fatality, adjusting for confounding factors. BMI was associated strongly with positive test, and risk of death related to COVID-19. The gradient of risk in relation to BMI was steeper in those under 70, compared with those aged 70 years or older for COVID-19 related death (Pinteraction=0.03). BMI was more strongly related to test positivity (Pinteraction=0.010) and death (Pinteraction=0.002) in non-whites, compared with whites. These data add support for adiposity being more strongly linked to COVID-19-related deaths in younger people and non-white ethnicities. If future studies confirm causality, lifestyle interventions to improve adiposity status may be important to reduce the risk of COVID-19 in all, but perhaps particularly, non-white communities.Competing Interest StatementNS reports personal fees from Amgen, AstraZeneca, Eli Lilly, Novo Nordisk, Pfizer, and Sanofi, and grants and personal fees from Boehringer Ingelheim, outside the submitted work. PW reports grant from Boehringer Ingelheim outside submitted work. All other authors declare no competing interests.Funding StatementNS, JMRG, SRG, CACM, JJVM and PW acknowledge relevant research support from a British Heart Foundation Research Excellence Award (RE/18/6/34217), and from MMI - Kuwait and Dasman Diabetes Institute, Kuwait. SVK acknowledges funding from an NRS Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC_UU_12017/13) and the Scottish Government Chief Scientist Office (SPHSU13).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data that generated our work is available from the UK biobank and can be replicated.